New Alzheimer's drug enters human testing phase
NCT ID NCT07328451
Summary
This early-stage study is testing the safety and how the body processes DNL628, an experimental drug for early Alzheimer's disease. It will involve 68 participants with mild memory problems and confirmed Alzheimer's brain changes. Researchers will monitor side effects, measure drug levels in the blood, and check for changes in Alzheimer's-related proteins in spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE, EARLY ONSET are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Site(s)
RECRUITINGLondon, WC1N 3BG, United Kingdom
Conditions
Explore the condition pages connected to this study.